BEIJING, Oct. 22, 2021 /PRNewswire/ -- Xiaobai Maimai Inc.
(NASDAQ: HX) ("Xiaobai Maimai," the "Company," or "we"), today
announced the appointment of Dr. Yingxian
Liu as the medical consultant to the Company. Dr. Liu will
work closely with management to develop the Company's cancer
therapy and radiation oncology business by the Company's
wholly-owned subsidiary, We Health Limited.
Dr. Liu received his medical degree from Sun Yat-sen University of Medical Sciences in
Guangzhou, China. He completed his
pathology residency at North Shore University Hospital in
Manhasset, New York. Dr. Liu
completed his hematopathology fellowship at Albert Einstein College
of Medicine at Montefiore Medical Center in the Bronx and his surgical pathology residency at
Mount Sinai Hospital in Manhattan.
Dr. Liu is board certified in anatomical pathology and serves on
the executive board of the Association of Chinese American
Physicians.
Ms. Yilin (Linda) Wang,
Chairwoman and Chief Executive Officer of Xiaobai Maimai,
commented, "We welcome the addition of Dr. Liu to the Company at
this pivotal time and look forward to his contributions to the
ongoing development of our radiation oncology business. As a
respected expert in the pathology field, Dr. Liu's guidance will
support our mission in assembling the necessary team and
infrastructure to build a best-in-class practice that's scalable
and delivers safe and high-quality cancer treatment to our
patients."
About Xiaobai Maimai Inc.
Xiaobai Maimai Inc. (NASDAQ: HX), formerly known as Hexindai
Inc., ("Xiaobai Maimai" or the "Company"), is currently engaged in
two lines of business, i.e. a social e-commerce platform
based in Beijing, China and the
planned cancer therapy and radiation oncology business.
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements are made under the "safe
harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These statements can be identified by terminology such
as "will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates," "potential," "continue," "ongoing,"
"targets," "guidance" and similar statements. The Company may also
make written or oral forward-looking statements in its periodic
reports to the U.S. Securities and Exchange Commission (the "SEC"),
in its annual report to shareholders, in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. Any statements that are
not historical facts, including statements about the Company's
beliefs and expectations, are forward-looking statements that
involve factors, risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements. Such factors and risks include, but not limited to the
following: risks related to our ability to obtain equipment,
technology, license and talents at satisfactory terms to start the
planned business, if at all; risks regarding the effect of the
COVID-19 pandemic on the Company and the Company's position in a
post-COVID-19 environment; risks related to the Company's ability
to adapt and make the necessary adjustments to compete and operate
effectively; risks related to decisions or changes in governmental
or private insurers' reimbursement levels for our radiotherapy
services or our ability to obtain reimbursement for our
radiotherapy services; risks related to increased competition and
the development of new competing services; the risk that we may be
unable to develop or achieve commercial success for radiotherapy
services in a timely manner, or at all; risks related to regulatory
requirements or enforcement in the United
States and changes in the structure of the healthcare system
or healthcare payment systems; risks related to our ability to
successfully integrate and derive benefits from any technologies
that we license or acquire; risks related to our projections about
our business, results of operations and financial condition; and
risks related to the potential market opportunity for our products
and services. Further information regarding these and other risks,
uncertainties or factors is included in the Company's filings with
the SEC. All information provided in this announcement is current
as of the date of this announcement, and the Company does not
undertake any obligation to update such information, except as
required under applicable law.
For more information, please visit
ir.xiaobaimaimai.com
For investor inquiries, please contact:
The Company
Investor Relations
Ms. Zenabo Ma
Email: ir@xiaobaimaimai.com
Christensen
In China
Mr. Eric Yuan
Phone: +86-10- 5900-1548
E-mail: Eyuan@christensenir.com
In US
Mr. Tip Fleming
Phone: +1-917-412-3333
Email: tfleming@Christensenir.com
View original
content:https://www.prnewswire.com/news-releases/xiaobai-maimai-appoints-dr-yingxian-liu-as-medical-consultant-for-we-health-limited-301406437.html
SOURCE Xiaobai Maimai Inc.